NCT06106009

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

A Multi-Part, Phase 1 Study With Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single- And Multiple-Dose Escalation To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-07976016 In Healthy Adult Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 117 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to learn if the study medicine (called PF-07976016) is safe and how it goes in and out of the body in healthy people. The study may also explore if PF-07976016 has the potential to interact with another medicine called midazolam. In addition, the study may explore how PF-07976016 goes into the body of people who have obesity.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-07976016	Oral solution, oral suspension or solid oral formulation(s)
DRUG	Placebo	Oral solution, oral suspension or solid oral formulation(s)
DRUG	Midazolam	Midazolam oral solution

Timeline

• Start date: 2023-10-27
• Primary completion: 2024-08-19
• Completion: 2024-08-19
• First posted: 2023-10-30
• Last updated: 2024-09-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study